MT-2271 (Mitsubishi Tanabe Pharma) Drug Overview 2019 - ResearchAndMarkets.com

DUBLIN--()--The "MT-2271" report has been added to ResearchAndMarkets.com's offering.

MT-2271 is a plant-based, recombinant virus-like particle (VLP) QIV seasonal influenza vaccine in development by Mitsubishi Tanabe Pharma. It contains a mix of recombinant hemagglutinin proteins expressed as VLPs. Based on Mitsubishi Tanabe Pharma's plan to complete the Phase III study in the elderly in 2019, the company intends to launch the vaccine in the US and EU for adults aged 18-64 years in time for the 2020/21 season (Mitsubishi Tanabe Pharma, 2018).

The author expects launch for the elderly in the 2021/22 season. The company anticipated starting Phase III trials in the pediatric population by the end of 2018, but as no trials have been initiated so far, the author expects the trials will not begin until H1 2019. Provided positive results are obtained in the pediatric population, the company could launch the vaccine as early as the 2022/23 season.

Research Outlook

MT-2271 is a plant-based, recombinant virus-like particle (VLP) QIV seasonal influenza vaccine in development by Mitsubishi Tanabe Pharma. It contains a mix of recombinant hemagglutinin proteins expressed as VLPs.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. MT-2271: Seasonal influenza vaccines

List of Tables

Table 1: MT-2271 drug profile

Table 2: Clinical trials of MT-2271 for seasonal influenza vaccination

Table 3: MT-2271 for seasonal influenza - SWOT analysis

For more information about this report visit https://www.researchandmarkets.com/r/4anpd

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines